U.S. markets closed

Clene Inc. (CLNN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.60+0.51 (+6.30%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close8.09
Open8.10
Bid7.35 x 800
Ask8.99 x 800
Day's Range8.03 - 8.65
52 Week Range6.23 - 17.82
Volume218,331
Avg. Volume471,284
Market Cap520.6M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.94
Earnings DateMay 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Clene to Host Expert Perspectives Webinar on Cellular Energetic Failure and the Unmet Medical Needs in ALS and MS
    GlobeNewswire

    Clene to Host Expert Perspectives Webinar on Cellular Energetic Failure and the Unmet Medical Needs in ALS and MS

    Webinar to take place on Wednesday, July 14, 2021 at 4:30 p.m. ETSALT LAKE CITY, June 30, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of cellular energetic failure in neurodegenerative disease using nanocatalysis, today announced it will host an expert perspectives webinar titled: “Cellular Energetic Failure: Addressing Unme

  • Clene Added to Membership of Russell 2000® Index
    GlobeNewswire

    Clene Added to Membership of Russell 2000® Index

    SALT LAKE CITY, June 28, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using bioenergetic nanocatalysis, today announced that it has been added as a member of the U.S. small-cap Russell 2000® Index and the all-cap Russell 3000® Index, effective after the U.S. market opens today, June 28, 2021, as p

  • Clene to Present at the Raymond James Human Health Innovation Conference
    GlobeNewswire

    Clene to Present at the Raymond James Human Health Innovation Conference

    SALT LAKE CITY, June 15, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using bioenergetic nanocatalysis, today announced that Rob Etherington, President and Chief Executive Officer, will present at the Raymond James Human Health Innovation Conference on Tuesday, June 22, 2021 at 11:20 a.m. ET. A we